SAN

80.32

-2.62%↓

UCB

262.5

-1.06%↓

SHL.DE

35.91

-0.08%↓

ARGX

649

+0.53%↑

VIE

33.44

+0.3%↑

SAN

80.32

-2.62%↓

UCB

262.5

-1.06%↓

SHL.DE

35.91

-0.08%↓

ARGX

649

+0.53%↑

VIE

33.44

+0.3%↑

SAN

80.32

-2.62%↓

UCB

262.5

-1.06%↓

SHL.DE

35.91

-0.08%↓

ARGX

649

+0.53%↑

VIE

33.44

+0.3%↑

SAN

80.32

-2.62%↓

UCB

262.5

-1.06%↓

SHL.DE

35.91

-0.08%↓

ARGX

649

+0.53%↑

VIE

33.44

+0.3%↑

SAN

80.32

-2.62%↓

UCB

262.5

-1.06%↓

SHL.DE

35.91

-0.08%↓

ARGX

649

+0.53%↑

VIE

33.44

+0.3%↑

Kodu・Aktsiate loetelu・Nanobiotix

N
Nanobiotix

Suletud

25.64 -6.76

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

25.1

Max

27.5

Põhinäitajad
By Trading Economics
Sissetulek	-5.4M
Müük	27M
Kasumimarginaal	-20.208
Töötajad	103
EBITDA	1.1M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+16.79% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	20. mai 2026

Turustatistika
By TradingEconomics
Turukapital	1.3B
Eelmine avamishind	32.4
Eelmine sulgemishind	25.64

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

2.975 / 3.015 Toetus ja vastupanu

Nanobiotix Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. apr 2026, 23:17 UTC

Tulu

Samsung Forecasts Record First-Quarter Operating Profit

6. apr 2026, 23:00 UTC

Kuumad aktsiad

Stocks to Watch: Health Insurers, Mawson, Owlet

6. apr 2026, 22:13 UTC

Suurimad hinnamuutused turgudel

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6. apr 2026, 21:46 UTC

Omandamised, ülevõtmised, äriostud

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6. apr 2026, 17:09 UTC

Suurimad hinnamuutused turgudel

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6. apr 2026, 16:56 UTC

Uudisväärsed sündmused

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6. apr 2026, 14:47 UTC

Suurimad hinnamuutused turgudel

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7. apr 2026, 00:00 UTC

Uudisväärsed sündmused

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6. apr 2026, 23:58 UTC

Market Talk

Uudisväärsed sündmused

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6. apr 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6. apr 2026, 23:36 UTC

Market Talk

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6. apr 2026, 23:15 UTC

Market Talk

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Global Equities Roundup: Market Talk

6. apr 2026, 22:52 UTC

Market Talk

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6. apr 2026, 22:14 UTC

Market Talk

Correction to Live Cattle Futures Article

6. apr 2026, 20:56 UTC

Market Talk

Mexican Private Consumption Fell in January -- Market Talk

6. apr 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

6. apr 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

6. apr 2026, 19:58 UTC

Market Talk

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6. apr 2026, 19:11 UTC

Market Talk

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6. apr 2026, 19:06 UTC

Market Talk

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Global Energy Roundup: Market Talk

6. apr 2026, 19:03 UTC

Market Talk

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6. apr 2026, 18:36 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 17:59 UTC

Market Talk

Uudisväärsed sündmused

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6. apr 2026, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6. apr 2026, 16:33 UTC

Market Talk

Oil Futures Steady as Market Awaits Trump -- Market Talk

6. apr 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. apr 2026, 14:59 UTC

Tulu

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

Nanobiotix Prognoos

Hinnasiht

By TipRanks

16.79% tõus

12 kuu keskmine prognoos

Keskmine 32 EUR 16.79%

Kõrge 32 EUR

Madal 32 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Nanobiotix 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Nanobiotix aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

2.975 / 3.015Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Nanobiotix

Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.